INTRAINDIVIDUAL COGNITIVE VARIABILITY IN AGING ADULTS WITH DOWN SYNDROME: ASSOCIATIONS WITH ALZHEIMER'S DIS…

Assistance award details

Assistance award identifier

ASST_NON_R00AG082864_075

FAIN

R00AG082864

Recipient

RUTGERS THE STATE UNIVERSITY OF NEW JERSEY

Awarding agency

Department of Health and Human Services

Funding agency

Department of Health and Human Services

Assistance listing (CFDA)

93.310

Total obligated

$493,938

Period

Aug 15, 2023 – May 31, 2028

Fiscal year

2025

Place of performance state

NJ

Source file

FY2025_All_Assistance_Full_20261006.zip

Description

INTRAINDIVIDUAL COGNITIVE VARIABILITY IN AGING ADULTS WITH DOWN SYNDROME: ASSOCIATIONS WITH ALZHEIMER'S DISEASE PLASMA BIOMARKERS, NEUROPATHOLOGY AND CLINICAL DEMENTIA - PROJECT SUMMARY/ABSTRACT INDIVIDUALS WITH DOWN SYNDROME (DS) ARE AT HIGHER RISK FOR DEVELOPING ALZHEIMER’S DISEASE (AD) COMPARED TO THE GENERAL POPULATION. AS SUCH, THEY ARE CONSIDERED AN IDEAL TARGET POPULATION FOR ANTI-AD THERAPY TRIALS; HOWEVER, THERE IS NO RELIABLE MEASURE FOR PREDICTING DEMENTIA ONSET IN THIS POPULATION. INTRAINDIVIDUAL COGNITIVE VARIABILITY (IICV), A MEASURE OF VARIABILITY IN NEUROPSYCHOLOGICAL TEST PERFORMANCE WITHIN A PERSON AT A SINGLE TIMEPOINT, IS A NOVEL, LOW-COST, NON-INVASIVE BIOMARKER OF NEURODEGENERATION AND EARLY DEMENTIA FOR THE GENERAL POPULATION. HOWEVER, IICV HAS NOT BEEN INVESTIGATED IN ADULTS WITH DS. THEREFORE, THE CURRENT PROPOSAL WILL FILL THIS KNOWLEDGE GAP BY CHARACTERIZING THE ASSOCIATIONS BETWEEN IICV, AD BIOMARKERS, AND DEMENTIA IN ADULTS WITH DS. AIMS 1 AND 2 OF THIS PROPOSAL USE DATA FROM THE ALZHEIMER’S BIOMARKER CONSORTIUM-DOWN SYNDROME (ABC-DS) STUDY, WHICH IS CURRENTLY COMPOSED OF COGNITIVE AND BIOMARKER DATA COLLECTED AT TWO DIFFERENT TIMEPOINTS (BASELINE AND 18 MONTHS), TO CALCULATE IICV MEASURES FOR MEMORY, EXECUTIVE FUNCTION AND PROCESSING SPEED, VISUOSPATIAL CONSTRUCTION, AND MULTIDOMAIN COGNITION IN 300 ADULTS WITH DS. USING THE LONGITUDINAL ABC- DS DATA, WE WILL FIRST EXAMINE WHETHER IICV IS ASSOCIATED WITH AD PLASMA BIOMARKERS (Β-AMYLOID 42/40, P- TAU217, AND NFL) AND/OR AD-RELATED PATHOLOGY (AΒ-PET AND TAU-PET) (K99, AIM 1). WE WILL ALSO EXAMINE WHETHER IICV IS ASSOCIATED WITH THE CLINICAL PRESENTATION OF DEMENTIA AND COGNITIVE DECLINE (K99, AIM 2). WE EXPECT OUR ANALYSES TO SHOW THAT IICV IS POSITIVELY ASSOCIATED WITH AD-RELATED BIOMARKERS AND PATHOLOGY, AND THAT IICV AT BASELINE IS ASSOCIATED WITH A FOLLOW-UP DIAGNOSIS OF DEMENTIA AS WELL AS COGNITIVE DECLINE FROM BASELINE TO FOLLOW-UP. THESE DATA WILL BE CRITICAL FOR OPTIMIZING